{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:46:47Z","timestamp":1794894407796,"version":"4.9.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.rmed.2024.107661","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:36:45Z","timestamp":1715168205000},"page":"107661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-6915","authenticated-orcid":false,"given":"Nazrul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2024.107661_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.rmed.2024.107661_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40248-018-0149-0","article-title":"Management of severe acute exacerbations of COPD: an updated narrative review","volume":"13","author":"Crisafulli","year":"2018","journal-title":"Multidiscip Respir Med."},{"key":"10.1016\/j.rmed.2024.107661_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMct1115170","article-title":"Antibiotic prevention of acute exacerbations of COPD","volume":"367","author":"Wenzel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107042","article-title":"Global morbidity and mortality of lower respiratory infections: a population -based study","volume":"205","author":"Yang","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics10010003","article-title":"Biofilms as promoters of bacterial antibiotic resistance and tolerance","volume":"10","author":"Uruen","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.rmed.2024.107661_bib6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1165\/rcmb.2017-0321TR","article-title":"Pseudomonas aeruginosa biofilms: host response and clinical implications in lung infections","volume":"58","author":"Maurice","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2024.107661_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/antibiotics12030484","article-title":"Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis","volume":"12","author":"Li","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.rmed.2024.107661_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000087686","article-title":"Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa","volume":"73","author":"Lechtzin","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2024.107661_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13054-020-2763-4","article-title":"Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial","volume":"24","author":"Ben\u00edtez-Cano","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.rmed.2024.107661_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2021.128028","article-title":"Disinfection of polymicrobial urines by electrochemical oxidation: removal of antibiotic-resistant bacteria and genes","volume":"426","author":"Herraiz-Carbone","year":"2022","journal-title":"J. Hazard Mater."},{"key":"10.1016\/j.rmed.2024.107661_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhin.2022.01.008","article-title":"Microbiome-based source identification of microbial contamination in nebulizers used by inpatients","volume":"122","author":"Swanson","year":"2022","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.rmed.2024.107661_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2015.1284","article-title":"Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire","volume":"30","author":"Hatley","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.rmed.2024.107661_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17425247.2018.1437414","article-title":"Use of spacers for patients treated with pressurized metered dose inhalers: focus on the VENTOLIN Mini Spacer","volume":"15","author":"Anderson","year":"2018","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.rmed.2024.107661_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.04.044","article-title":"Dry powder inhalers (DPIs)-A review of device reliability and innovation","volume":"360","author":"Islam","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.rmed.2024.107661_bib15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jps.10583","article-title":"Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures","volume":"93","author":"Islam","year":"2004","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.rmed.2024.107661_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1023\/B:PHAM.0000019304.91412.18","article-title":"Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?","volume":"21","author":"Islam","year":"2004","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.rmed.2024.107661_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105857","article-title":"The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease","volume":"161","author":"Mahler","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib18","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.3390\/jcm12103577","article-title":"Efficacy and safety of dry powder antibiotics: a narrative review","volume":"12","author":"de la Rosa-Carrillo","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41533-022-00318-3","article-title":"Clinical recommendations for dry powder inhaler use in the management of COPD in primary care","volume":"32","author":"Leving","year":"2022","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.rmed.2024.107661_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.biomaterials.2018.01.022","article-title":"Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia","volume":"160","author":"Wang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.rmed.2024.107661_bib21","first-page":"1233","article-title":"[Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus]","volume":"33","author":"Shirai","year":"1995","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi"},{"key":"10.1016\/j.rmed.2024.107661_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01776-19","article-title":"Phase I, dose-escalating study of the safety and pharmacokinetics of inhaled dry-powder vancomycin (AeroVanc) in volunteers and patients with cystic fibrosis: a new approach to therapy for Methicillin-resistant Staphylococcus aureus","volume":"64","author":"Waterer","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00316-21","article-title":"Development and preclinical evaluation of new inhaled lipoglycopeptides for the treatment of persistent pulmonary methicillin-resistant Staphylococcus aureus infections","volume":"65","author":"Plaunt","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/membranes13020141","article-title":"Phosphatidylcholine liposomes reprogram macrophages toward an inflammatory phenotype","volume":"13","author":"Cauvi","year":"2023","journal-title":"Membranes"},{"key":"10.1016\/j.rmed.2024.107661_bib25","doi-asserted-by":"crossref","first-page":"15792","DOI":"10.1021\/acsnano.2c04232","article-title":"Designer liposomic nanocarriers are effective biofilm eradicators","volume":"16","author":"Kluzek","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.rmed.2024.107661_bib26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled liposomal antimicrobial delivery in lung infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2024.107661_bib27","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/AAC.00700-16","article-title":"Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats","volume":"60","author":"Malinin","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib28","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jam.15053","article-title":"Liposome as a delivery system for the treatment of biofilm-mediated infections","volume":"131","author":"Wang","year":"2021","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.rmed.2024.107661_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2019.08.001","article-title":"Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"19","author":"Bilton","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107661_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261720","article-title":"Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections","volume":"16","author":"Sabuj","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2024.107661_bib31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/ph15101223","article-title":"Stability of inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticle dry powder inhaler formulation in high stressed conditions","volume":"15","author":"Sabuj","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.rmed.2024.107661_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054532","article-title":"Cytotoxic and bactericidal effects of inhalable ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles with traces of zinc oxide","volume":"24","author":"Sabuj","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.rmed.2024.107661_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2008.09.043","article-title":"The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell","volume":"367","author":"Drulis-Kawa","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.rmed.2024.107661_bib34","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/fmb-2018-0194","article-title":"Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections","volume":"13","author":"Ritsema","year":"2018","journal-title":"Future Microbiol."},{"key":"10.1016\/j.rmed.2024.107661_bib35","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2217\/fmb.15.117","article-title":"Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin","volume":"10","author":"Ehsan","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.rmed.2024.107661_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2013.04.069","article-title":"Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis","volume":"451","author":"Pilcer","year":"2013","journal-title":"Int. J. Pharm. (Amst.)"},{"key":"10.1016\/j.rmed.2024.107661_bib37","article-title":"Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections","volume":"575","author":"Yu","year":"2020","journal-title":"Int. J. Pharm. (Amst.)"},{"key":"10.1016\/j.rmed.2024.107661_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.rmed.2024.107661_bib39","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1039\/D1NA00205H","article-title":"Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections","volume":"3","author":"Rahman Sabuj","year":"2021","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.rmed.2024.107661_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","volume":"117","author":"Guenday Tuereli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.rmed.2024.107661_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2013.04.009","article-title":"Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity","volume":"449","author":"Osman","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.rmed.2024.107661_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119684","article-title":"Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery","volume":"587","author":"Muneer","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.rmed.2024.107661_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/46.2.319","article-title":"Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid","volume":"46","author":"Allegranzi","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib44","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/jac\/dky370","article-title":"Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections","volume":"73","author":"Burger","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.colsurfb.2015.08.027","article-title":"Overcoming barriers in Pseudomonas aeruginosa lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide","volume":"135","author":"d'Angelo","year":"2015","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.rmed.2024.107661_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2014.11.022","article-title":"Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase)","volume":"198","author":"Deacon","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.rmed.2024.107661_bib47","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2217\/fmb-2021-0150","article-title":"Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis","volume":"16","author":"Elborn","year":"2021","journal-title":"Future Microbiol."},{"key":"10.1016\/j.rmed.2024.107661_bib48","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/jps.23508","article-title":"Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies","volume":"102","author":"Wallace","year":"2013","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.rmed.2024.107661_bib49","doi-asserted-by":"crossref","first-page":"1702052\/1","DOI":"10.1183\/13993003.02052-2017","article-title":"Respire 1: a phase iii placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107661_bib50","doi-asserted-by":"crossref","first-page":"1702053\/1","DOI":"10.1183\/13993003.02053-2017","article-title":"Respire 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107661_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib52","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107661_bib53","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jcf.2020.12.012","article-title":"The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: an open-label randomised crossover study (AZTEC-CF)","volume":"20","author":"Frost","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107661_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arbres.2021.03.009","article-title":"Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study","volume":"58","author":"De la Rosa Carrillo","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.rmed.2024.107661_bib55","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17476348.2018.1503540","article-title":"Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials","volume":"12","author":"Paredes Aller","year":"2018","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/jamp.2021.0023","article-title":"The unfulfilled promise of inhaled therapy in ventilator-associated infections: where do we go from here?","volume":"35","author":"Palmer","year":"2022","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.rmed.2024.107661_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107661_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ppul.21521","article-title":"Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2024.107661_bib59","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2024.107661_bib60","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s11095-022-03379-8","article-title":"Pulmonary delivery of emerging antibacterials for bacterial lung infections treatment","volume":"40","author":"Li","year":"2023","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.rmed.2024.107661_bib61","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2024.107661_bib62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.rmed.2024.107661_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106728","article-title":"Bronchiectasis and inhaled tobramycin: a literature review","volume":"192","author":"Elborn","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107661_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chest.2022.09.003","article-title":"Randomized clinical trials of inhaled antibiotics in bronchiectasis","volume":"163","author":"Wong","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2024.107661_bib65","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jinf.2013.08.010","article-title":"Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease","volume":"67","author":"Wilson","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.rmed.2024.107661_bib66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","article-title":"Antibiotics in the clinical pipeline as of December 2022","volume":"76","author":"Butler","year":"2023","journal-title":"J. Antibiot."},{"key":"10.1016\/j.rmed.2024.107661_bib67","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1021\/acs.jmedchem.8b01781","article-title":"Antibiotic adjuvants: make antibiotics great again","volume":"62","author":"Douafer","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.rmed.2024.107661_bib68","first-page":"CD008037","article-title":"Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis","volume":"7","author":"Hurley","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2024.107661_bib69","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1128\/AAC.38.9.2125","article-title":"Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms","volume":"38","author":"Suci","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib70","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/AAC.41.6.1352","article-title":"Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa biofilms displaying rapid-transport characteristics","volume":"41","author":"Vrany","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2024.107661_bib71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/jacsau.2c00532","article-title":"Chemical basis of combination therapy to combat antibiotic resistance","volume":"3","author":"Si","year":"2023","journal-title":"JACS Au"},{"key":"10.1016\/j.rmed.2024.107661_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106654","article-title":"Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis","volume":"192","author":"Alhajj","year":"2024","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.rmed.2024.107661_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121657","article-title":"Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system","volume":"618","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.rmed.2024.107661_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","article-title":"Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients","volume":"21","author":"Chang","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.rmed.2024.107661_bib75","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.rmed.2024.107661_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119952","article-title":"Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections","volume":"591","author":"Lin","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.rmed.2024.107661_bib77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/pharmrev.123.000863","article-title":"Halogenated antimicrobial agents to combat drug-resistant pathogens","volume":"76","author":"Faleye","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.rmed.2024.107661_bib78","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","article-title":"Ventilator-associated pneumonia in adults: a narrative review","volume":"46","author":"Papazian","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.rmed.2024.107661_bib79","first-page":"159","article-title":"Ventilator-associated pneumonia: a problematic outcome for clinical trials","volume":"25","author":"Young","year":"2023","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.rmed.2024.107661_bib80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QCO.0000000000000525","article-title":"Why have trials of inhaled antibiotics for ventilator-associated infections failed?","volume":"32","author":"Palmer","year":"2019","journal-title":"Curr. Opin. Infect. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T21:17:10Z","timestamp":1717276630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124001355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":80,"alternative-id":["S0954611124001355"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107661","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107661"}}